We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Presents Comprehensive Clinical Chemistry and Immunoturbidimetry Solutions

By LabMedica International staff writers
Posted on 19 Nov 2025

At MEDICA 2025, DiaSys Diagnostic Systems GmbH presents a comprehensive portfolio of diagnostic solutions focused on clinical chemistry and immunoturbidimetry. More...

Diasys is exhibiting at Hall 3, Stand D44 where it is highlighting more than three decades of experience supplying laboratories in over 140 countries.

DiaSys offers a broad range of more than 90 ready-to-use reagents covering routine chemistry, lipid testing, liver and kidney function, coagulation-related markers, inflammatory biomarkers and special immunoturbidimetric assays. Calibrators and controls complement the reagent portfolio, providing complete system solutions for laboratories that require traceable, quality-assured testing components.

Products being featured at MEDICA 2025 include the Procalcitonin FS assay for rapid sepsis diagnosis, now available for the DiaSys respons systems and the BioMajesty JCA-BM6010/C. Also highlighted is the Total Bile Acids 21 FS assay, suitable for determining total bile acids in human serum and stool, serving as a sensitive marker of liver function and the primary marker for intrahepatic cholestasis of pregnancy. DiaSys has further expanded its cardiovascular risk assessment portfolio with two new reagents, HDL-c direct FS and LDL-c direct FS, both homogeneous assays designed for direct measurement.

DiaSys is additionally emphasizing its instrumentation portfolio, engineered to integrate seamlessly with its reagents. The respons c-line analyzers, including the respons 240c, respons 420c, and respons 600c, offer efficient and reliable testing options for small to medium-sized laboratories. The company is also showcasing specialized systems such as the respons A1c, an easy-to-use analyzer that enables rapid and reliable HbA1c determination from capillary blood using boronate affinity chromatography. Also on display is the newly launched respons UDS100, a compact urine analyzer designed to deliver fast and precise results using a dedicated 12-parameter test strip that includes standard parameters along with ACR.

Related Links:
DiaSys Diagnostics Systems


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.